Summary
Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome - Pipeline Review, H1 2016’, provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
- The report reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Acute Respiratory Distress Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Altor BioScience Corporation
Athersys, Inc.
Faron Pharmaceuticals Oy
FirstString Research, Inc.
GlaxoSmithKline Plc
Histocell S.L.
Phylogica Limited
Serendex Pharmaceuticals A/S
Silence Therapeutics Plc
Therabron Therapeutics, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Respiratory Distress Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Respiratory Distress Syndrome - Overview 10
Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis 11
Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies 12
Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes 13
Acute Respiratory Distress Syndrome - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acute Respiratory Distress Syndrome - Products under Development by Companies 17
Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes 18
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development 19
Altor BioScience Corporation 19
Athersys, Inc. 20
Faron Pharmaceuticals Oy 21
FirstString Research, Inc. 22
GlaxoSmithKline Plc 23
Histocell S.L. 24
Phylogica Limited 25
Serendex Pharmaceuticals A/S 26
Silence Therapeutics Plc 27
Therabron Therapeutics, Inc. 28
Acute Respiratory Distress Syndrome - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
ALT-836 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BIO-10901 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CG-367 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cyndacel-M - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GSK-2586881 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GSK-2862277 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
interferon beta-1a - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
molgramostim - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PF-05285401 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PYC-35 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
PYC-36 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PYC-38 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PYC-98 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
S-1229 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SAN-101 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Stromal Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Acute Respiratory Distress Syndrome - Recent Pipeline Updates 69
Acute Respiratory Distress Syndrome - Dormant Projects 81
Acute Respiratory Distress Syndrome - Discontinued Products 82
Acute Respiratory Distress Syndrome - Product Development Milestones 83
Featured News & Press Releases 83
Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS 83
Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome 83
Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP 84
Aug 09, 2015: Serendex to initiate first phase II clinical trial 85
Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November 85
May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced 86
May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases 86
May 10, 2015: Positive topline data from Serendex phase I clinical trial 87
Feb 27, 2015: Serendex submits phase I application 88
Feb 13, 2015: Serendex partners up with leading German lung center 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91
List of Tables
Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2016 10
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H1 2016 19
Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H1 2016 20
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2016 21
Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H1 2016 22
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2016 23
Acute Respiratory Distress Syndrome - Pipeline by Histocell S.L., H1 2016 24
Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H1 2016 25
Acute Respiratory Distress Syndrome - Pipeline by Serendex Pharmaceuticals A/S, H1 2016 26
Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H1 2016 27
Acute Respiratory Distress Syndrome - Pipeline by Therabron Therapeutics, Inc., H1 2016 28
Assessment by Monotherapy Products, H1 2016 29
Number of Products by Stage and Target, H1 2016 31
Number of Products by Stage and Mechanism of Action, H1 2016 33
Number of Products by Stage and Route of Administration, H1 2016 35
Number of Products by Stage and Molecule Type, H1 2016 37
Acute Respiratory Distress Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 69
Acute Respiratory Distress Syndrome - Dormant Projects, H1 2016 81
Acute Respiratory Distress Syndrome - Discontinued Products, H1 2016 82
List of Figures
Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2016 10
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 29
Number of Products by Top 10 Targets, H1 2016 30
Number of Products by Stage and Top 10 Targets, H1 2016 30
Number of Products by Top 10 Mechanism of Actions, H1 2016 32
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 32
Number of Products by Routes of Administration, H1 2016 34
Number of Products by Stage and Routes of Administration, H1 2016 34
Number of Products by Molecule Types, H1 2016 36
Number of Products by Stage and Molecule Types, H1 2016 36
